Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
58.26 EUR | -1.65% | +1.04% | -1.22% |
May. 13 | Eurofins Scientific to Expand US Battery Materials Testing Capabilities | MT |
May. 13 | Eurofins Scientific expands capacity in the USA | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company is in debt and has limited leeway for investment
- With a 2024 P/E ratio at 28.85 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.22% | 12.22B | A- | ||
+19.28% | 84.56B | C+ | ||
-26.95% | 72.41B | B- | ||
+4.65% | 27.75B | C+ | ||
-7.35% | 17.75B | B | ||
-0.46% | 17.11B | A- | ||
+4.69% | 16.03B | A- | ||
+8.14% | 13.72B | B- | ||
+6.59% | 12.91B | A- | ||
+70.00% | 12.55B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ERF Stock
- Ratings Eurofins Scientific SE